Quênia - inglês - Pharmacy and Poisons Board

life care pharmaceuticals ltd p.o. box 8379-30100, nairobi, kenya - benzylpenicillin sodium - powder and solvent for intravesical solution - each vial contains: benzylpenicillin sodium 1mega… - benzylpenicillin

Malta - inglês - Medicines Authority

cooper s.a. pharmaceuticals 64 aristovoulou str, 11853 k. petralona, athens, greece - benzylpenicillin sodium - powder for solution for injection - benzylpenicillin sodium 1000000 iu - antibacterials for systemic use

Malta - inglês - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - benzylpenicillin sodium - powder for injection - benzylpenicillin sodium 600 milligram(s) - antibacterials for systemic use

Quênia - inglês - Pharmacy and Poisons Board

benzyl penicillin sodium 5mu - injection - 5mu - benzylpenicillin

Quênia - inglês - Pharmacy and Poisons Board

benzyl penicillin 1mu - injection - 1mu - benzylpenicillin

Quênia - inglês - Pharmacy and Poisons Board

benzylpenicillin sodium - powder for injection - 1 mega / vial - benzylpenicillin

Quênia - inglês - Pharmacy and Poisons Board

benzylpenicillin sodium - powder for injection - 5 mega / vial - benzylpenicillin

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - benzyl benzoate 25%{relative};  ;  ;   - topical emulsion - 25% w/v - active: benzyl benzoate 25%{relative}       excipient: cetostearyl alcohol methyl hydroxybenzoate propyl hydroxybenzoate purified water sodium laurilsulfate

Estados Unidos - inglês - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1), misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - diclofenac sodium 50 mg - arthrotec is indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing nsaid-induced gastric and duodenal ulcers and their complications. for a list of factors that may increase the risk of nsaid-induced gastric and duodenal ulcers and their complications [see warnings and precautions (5.2)] . arthrotec is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac sodium/misoprostol, other prostaglandins, or any components of the drug product [see warnings and precautions (5.7, 5.9)] known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac sodium/misoprostol, other prostaglandins, or any components of the drug product [see warnings and precautions (5.7, 5.9)] - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids

Estados Unidos - inglês - NLM (National Library of Medicine)

lake erie medical & surgical supply dba quality care products llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1), misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - diclofenac sodium 75 mg - carefully consider the potential benefits and risks of arthrotec and other treatment options before deciding to use arthrotec. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). arthrotec is indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing nsaid-induced gastric and duodenal ulcers and their complications. see warnings, gastrointestinal effects - risk of ulceration, bleeding, and perforation for a list of factors that may increase the risk of nsaid-induced gastric and duodenal ulcers and their complications. see boxed contraindications and warnings related to misoprostol. arthrotec should not be taken by pregnant women. arthrotec is contraindicated in patients with hypersensitivity to diclofenac or to misoprostol or other prostaglandins. arthrotec should not be given to patients who have experienced asthma, urticaria, or other allergic-type reactions after